23:06:19 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss.

Kalender

2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017
2021-06-24 11:48:44
Moss, 24 June 2021

Reference is made to the announcement made by Gentian Diagnostics ASA (the
"Company") on 7 May 2021 where it was announced that the Company had submitted
an application for admission to trading on Oslo Børs (the "Listing") by transfer
of its current admission to trading on Euronext Growth Oslo. The application was
approved on 23 June 2021.

The first day of trading of the Company's shares on Oslo Børs' main list is
expected to be on 25 June 2021. Consequently, the last day of trading of the
Company's shares on Euronext Growth Oslo is expected to be today, 24 June 2021.

The Company has prepared a prospectus in connection with the Listing (the
"Prospectus"), which has been approved by the Norwegian Financial Supervisory
Authority. The Prospectus is available at:

www.gentian.com/investor-relations-stock-information/key-information-investors/

Hard copies of the Prospectus may be obtained free of charge at the Company's
registered business address Bjørnåsveien 5, 1596 Moss, Norway (subject to
prevailing restrictions due to the Covid-19 pandemic).

AGP Advokater AS has acted as legal counsel to the Company in connection with
the Listing and Advokatfirmaet Selmer AS and Moore Consulting AS have acted as
due diligence advisors.

For further information please contact:
Hilja Ibert CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525